Jubilant Pharmova Crecimiento futuro
Future controles de criterios 0/6
Actualmente no disponemos de suficiente cobertura de analistas para prever el crecimiento y los ingresos de Jubilant Pharmova.
Información clave
n/a
Tasa de crecimiento de los beneficios
n/a
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 19.0% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | None |
| Última actualización | n/a |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14
Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
Shareholders Are Thrilled That The Jubilant Life Sciences (NSE:JUBILANT) Share Price Increased 217%
Jan 11Does Jubilant Life Sciences' (NSE:JUBILANT) CEO Salary Compare Well With Industry Peers?
Dec 31Read This Before Selling Jubilant Life Sciences Limited (NSE:JUBILANT) Shares
Dec 20Has Jubilant Life Sciences Limited's (NSE:JUBILANT) Impressive Stock Performance Got Anything to Do With Its Fundamentals?
Dec 08We Think Jubilant Life Sciences (NSE:JUBILANT) Can Stay On Top Of Its Debt
Nov 27What Kind Of Investors Own Most Of Jubilant Life Sciences Limited (NSE:JUBILANT)?
Nov 17Jubilant Life Sciences Limited Just Missed EPS By 15%: Here's What Analysts Think Will Happen Next
Nov 06If You Like EPS Growth Then Check Out Jubilant Life Sciences (NSE:JUBILANT) Before It's Too Late
Oct 27Estimating The Fair Value Of Jubilant Life Sciences Limited (NSE:JUBILANT)
Oct 15Does Jubilant Life Sciences' (NSE:JUBILANT) Share Price Gain of 96% Match Its Business Performance?
Oct 03Trade Alert: The Independent Non-Executive Director Of Jubilant Life Sciences Limited (NSE:JUBILANT), Arun Seth, Has Just Spent ₹1.1m Buying 233% More Shares
Sep 21How Much is Jubilant Life Sciences' (NSE:JUBILANT) CEO Getting Paid?
Sep 20Jubilant Life Sciences Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Sep 08Should You Take Comfort From Insider Transactions At Jubilant Life Sciences Limited (NSE:JUBILANT)?
Sep 03Jubilant Life Sciences Limited's (NSE:JUBILANT) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Aug 24En esta sección solemos presentar previsiones de crecimiento de ingresos y beneficios basadas en las estimaciones por consenso de analistas profesionales para ayudar a los inversores a comprender la capacidad de la empresa para generar beneficios. Pero como Jubilant Pharmova no ha proporcionado suficientes datos anteriores y no dispone de previsiones de analistas, sus beneficios futuros no pueden calcularse de forma fiable extrapolando datos anteriores o utilizando las previsiones de los analistas.
Es una situación poco común, ya que el 97% de las empresas disponibles en SimplyWall St sí disponen de datos financieros anteriores.
Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2023 | 66,223 | 378 | N/A | N/A | N/A |
| 9/30/2023 | 64,977 | -446 | 133 | 9,836 | N/A |
| 6/30/2023 | 64,169 | -1,017 | N/A | N/A | N/A |
| 3/31/2023 | 62,817 | -610 | -1,538 | 6,607 | N/A |
| 12/31/2022 | 61,313 | 964 | N/A | N/A | N/A |
| 9/30/2022 | 58,893 | 1,631 | -1,596 | 4,924 | N/A |
| 6/30/2022 | 59,472 | 3,004 | N/A | N/A | N/A |
| 3/31/2022 | 61,302 | 4,139 | 2,376 | 8,375 | N/A |
| 12/31/2021 | 61,824 | 5,273 | N/A | N/A | N/A |
| 9/30/2021 | 66,432 | 6,953 | 10,175 | 16,021 | N/A |
| 6/30/2021 | 65,771 | 6,993 | N/A | N/A | N/A |
| 3/31/2021 | 60,985 | 5,741 | 12,568 | 17,843 | N/A |
| 12/31/2020 | 92,659 | 8,339 | N/A | N/A | N/A |
| 9/30/2020 | 89,744 | 7,759 | 10,031 | 15,596 | N/A |
| 6/30/2020 | 88,655 | 8,013 | N/A | N/A | N/A |
| 3/31/2020 | 59,758 | 6,778 | 9,688 | 15,429 | N/A |
| 12/31/2019 | 91,486 | 5,385 | N/A | N/A | N/A |
| 9/30/2019 | 92,105 | 5,959 | 7,357 | 13,374 | N/A |
| 6/30/2019 | 92,140 | 5,569 | N/A | N/A | N/A |
| 3/31/2019 | 91,108 | 5,745 | 4,656 | 11,215 | N/A |
| 12/31/2018 | 89,772 | 8,286 | N/A | N/A | N/A |
| 9/30/2018 | 86,679 | 7,803 | N/A | N/A | N/A |
| 6/30/2018 | 80,402 | 6,982 | N/A | N/A | N/A |
| 3/31/2018 | 75,178 | 6,428 | 8,141 | 13,032 | N/A |
| 12/31/2017 | 68,641 | 6,381 | N/A | N/A | N/A |
| 9/30/2017 | 62,545 | 5,449 | N/A | N/A | N/A |
| 6/30/2017 | 59,982 | 5,613 | N/A | N/A | N/A |
| 3/31/2017 | 58,614 | 5,757 | N/A | 12,685 | N/A |
| 12/31/2016 | 58,013 | 4,763 | N/A | N/A | N/A |
| 9/30/2016 | 57,097 | 4,795 | N/A | N/A | N/A |
| 6/30/2016 | 57,762 | 4,612 | N/A | N/A | N/A |
| 3/31/2016 | 57,491 | 3,918 | N/A | 10,989 | N/A |
| 12/31/2015 | 58,376 | 4,035 | N/A | N/A | N/A |
| 9/30/2015 | 59,036 | 2,754 | N/A | N/A | N/A |
| 6/30/2015 | 58,117 | 655 | N/A | N/A | N/A |
| 3/31/2015 | 58,262 | -578 | N/A | 7,833 | N/A |
| 12/31/2014 | 58,863 | -17 | N/A | N/A | N/A |
| 9/30/2014 | 58,837 | 1,529 | N/A | N/A | N/A |
| 6/30/2014 | 58,641 | 1,664 | N/A | N/A | N/A |
| 3/31/2014 | 58,034 | 1,090 | N/A | 7,723 | N/A |
| 12/31/2013 | 55,983 | -207 | N/A | N/A | N/A |
| 9/30/2013 | 54,658 | -1,375 | N/A | N/A | N/A |
| 6/30/2013 | 52,497 | 951 | N/A | N/A | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. tasa de ahorro: Datos insuficientes para determinar si el crecimiento previsto de los beneficios de JUBLPHARMA es superior a la tasa de ahorro (6.7%).
Beneficios frente mercado: Datos insuficientes para determinar si se prevé que los beneficios de JUBLPHARMA crezcan más deprisa que el mercado Indian
Beneficios de alto crecimiento: Datos insuficientes para determinar si se espera que los beneficios de JUBLPHARMA crezcan significativamente en los próximos 3 años.
Ingresos vs. Mercado: No hay datos suficientes para determinar si se prevé que los ingresos de JUBLPHARMA crezcan más rápido que el mercado de Indian.
Ingresos de alto crecimiento: No hay datos suficientes para determinar si se prevé que los ingresos de JUBLPHARMA crezcan a un ritmo superior a 20% al año.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
Futura rentabilidad financiera (ROE): Datos insuficientes para determinar si la Rentabilidad de los fondos propios de JUBLPHARMA se prevé elevada dentro de 3 años.